Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.63 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5268593 | 0.83 | GPR119 (0.65) | GPR119USP30CHEK2ALDH1A1 | |
| SCHEMBL12545179 | 0.82 | GPR119 (0.51) | GPR119NPBWR1MCHR1 | |
| SCHEMBL5239182 | 0.81 | GPR119 (0.63) | GPR119CHEK2ALDH1A1 | |
| SCHEMBL8166625 | 0.80 | GPR119 (0.51) | GPR119NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL74203 | 0.80 | GPR119 (0.67) | GPR119USP30CHEK2ALDH1A1 | |
| SCHEMBL264162 | 0.80 | GPR119 (0.67) | GPR119USP30CHEK2ALDH1A1 | |
| SCHEMBL12533230 | 0.80 | GPR119 (0.67) | GPR119CHEK2ALDH1A1 | |
| SCHEMBL2735422 | 0.80 | GPR119 (0.67) | GPR119USP30NPBWR1MCHR1CHEK2 | |
| SCHEMBL8271857 | 0.79 | GPR119 (0.51) | GPR119NPBWR1MCHR1 | |
| SCHEMBL22387771 | 0.79 | GPR119 (0.60) | GPR119USP30CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158652-B2 | 1-Difluoromethyl-5-{4-[3-(1-piperidinyl)propoxy]phenyl}-2(1H)-pyridone; compounds act as histamine-H3 receptor antagonistic substances or inverse-agonistic substances; useful as preventives or remedies for various circular system diseases, nervous system diseases, metabolic system diseases | MSD K.K. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20080269287-A1 | Substituted Pyridone Derivative | MSD K.K. (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1820797-A1 | SUBSTITUTED PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269287-A1 | Substituted Pyridone Derivative | HRH3, HRH4, HRH1 | GPR119 10/4885USP30 2386/4885NPBWR1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.